^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
finotonlimab (SCT-I10A)
i
Other names: SCT-I10A, SCT-I10, SCT I10A, SCTI10A
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sinocelltech
Drug class:
PD1 inhibitor
Related drugs:
9ms
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer (clinicaltrials.gov)
P3, N=188, Terminated, Sinocelltech Ltd. | N=360 --> 188 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2022 --> Feb 2023; Strategy adjustments, independent of the safety and efficacy of the trial medication
Enrollment change • Trial termination • Trial primary completion date • Metastases
|
EGFR mutation
|
docetaxel • finotonlimab (SCT-I10A)
10ms
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P2/3, N=405, Active, not recruiting, Sinocelltech Ltd. | Recruiting --> Active, not recruiting
Enrollment closed
|
sorafenib • Ambezhu (bevacizumab biosimilar) • finotonlimab (SCT-I10A)
11ms
Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer. (PubMed, Cancer Biol Med)
SCT200 combined with SCT-I10A demonstrated promising efficacy in previously treated RAS/BRAF wt mCRC patients with an acceptable safety profile. Further head-to-head studies with larger sample sizes are needed to validate whether the efficacy and safety of combined anti-EGFR and anti-PD-1 therapy are superior to anti-EGFR monotherapy in the third-line setting. (Registration No. NCT04229537).
P1 data • Journal • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
|
BRAF wild-type
|
SCT200 • finotonlimab (SCT-I10A)
2years
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P1, N=120, Recruiting, Sinocelltech Ltd.
New P1 trial • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
paclitaxel • docetaxel • SCT200 • finotonlimab (SCT-I10A)
almost5years
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P3, N=330, Recruiting, Sinocelltech Ltd. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
finotonlimab (SCT-I10A)
almost5years
Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=103, Recruiting, Sinocelltech Ltd. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
finotonlimab (SCT-I10A)
Share via
